Keymed Biosciences, Inc. ( (HK:2162) ) has shared an update.
Keymed Biosciences Inc. has announced a board meeting scheduled for March 24, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a company incorporated in the Cayman Islands, operating in the biotechnology sector. It focuses on developing innovative medical solutions and products, primarily targeting the healthcare market.
YTD Price Performance: 13.75%
Average Trading Volume: 1,844,939
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$9.2B
Find detailed analytics on 2162 stock on TipRanks’ Stock Analysis page.